CANGIALOSI LORETTA V 4

4 · PFIZER INC · Filed Mar 1, 2019

Form 4

Period: 2019-02-27

Sr. Vice President, Controller

Transactions

Exercise/Conversion
Common Stock
[F1]
2019-02-27$32.23/sh+25,729$829,246→ 121,743 total
Award
Common Stock
[F2]
2019-02-27+8,017→ 129,760 total
Tax Payment
Common Stock
[F3]
2019-02-27$42.93/sh−3,926$168,543→ 125,834 total
Tax Payment
Common Stock
[F4]
2019-02-27$42.93/sh−4,819$206,880→ 121,015 total
Tax Payment
Common Stock
[F5][F6]
2019-02-27$42.31/sh−15,890$672,306→ 105,125 total
Award
Common Stock
[F7]
2019-02-28+3,482→ 108,607 total
Exercise/Conversion
Stock Appreciation Rights
2019-02-27−25,729→ 0 total
Exercise: $32.23From: 2019-02-27Exp: 2019-02-27→ Common Stock (25,729 underlying)
Award
Stock Appreciation Rights
[F8]
2019-02-28+18,050→ 18,050 total
Exercise: $43.35From: 2024-02-28Exp: 2024-02-28→ Common Stock (18,050 underlying)
Award
Stock Appreciation Rights
[F9]
2019-02-28+15,211→ 15,211 total
Exercise: $43.35From: 2026-02-28Exp: 2026-02-28→ Common Stock (15,211 underlying)

Holdings

Footnotes (9)

[F1]The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
[F2]The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon).
[F3]The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon).
[F4]The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
[F5]The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
[F6]Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
[F7]The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.
[F8]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
[F9]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

Signature

Susan E. Grant, by power of atty., for Loretta V. Cangialosi|2019-03-01

Documents

1 file